November 28, 2018
麻豆传媒在线 School of Medicine
麻豆传媒在线 Hospital
On November 27, the Type 1 regenerative medicine provision plan, which outlines the details of the clinical research on "regenerative medicine for subacute spinal cord injury using iPS cell-derived neural stem/progenitor cells" being advanced by Professor Hideyuki Okano of the Department of Physiology and Professor Masaya Nakamura of the Department of Orthopedic Surgery at the 麻豆传媒在线 School of Medicine, received a decision (so-called "approval") from 麻豆传媒在线's Specified Certified Committee for Regenerative Medicine. This decision confirms that the plan conforms to the standards for providing regenerative medicine as stipulated by the Act on the Safety of Regenerative Medicine and its Ordinance for Enforcement.
Going forward, the 麻豆传媒在线 School of Medicine and 麻豆传媒在线 Hospital will proceed without delay with the necessary procedures to conduct the clinical trials aimed at realizing this new treatment method. This includes submitting this provision plan to the Minister of Health, Labour and Welfare, in accordance with the provisions of the Act on the Safety of Regenerative Medicine and its Ordinance for Enforcement.
Please see below for the full press release.